BIO (Bio-Rad Laboratories) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIO Bio-Rad Laboratories Inc BIO
70 GF Score
Price $376.41
GF Value $316.02
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bio-Rad Laboratories  (NYSE:BIO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bio-Rad Laboratories Cyclically Adjusted PB Ratio Related Terms


Bio-Rad Laboratories Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Cyclically Adjusted PB Ratio Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.32 2.01 1.36 1.28 1.08

Bio-Rad Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 1.05 1.12 1.00 1.03

BIO vs PODD, GKOS, GMED: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Cyclically Adjusted PB Ratio falls into.


BIO
70GF Score
Bio-Rad Laboratories Inc BIO
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bio-Rad Laboratories's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Bio-Rad Laboratories's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=268.303/333.9520*333.9520
=268.303

Current CPI (Jun. 2026) = 333.9520.

Bio-Rad Laboratories Quarterly Data

Book Value per Share CPI Adj_Book
201609 91.489 241.428 126.551
201612 87.459 241.432 120.974
201703 91.451 243.801 125.267
201706 94.901 244.955 129.380
201709 95.702 246.819 129.487
201712 98.379 246.524 133.268
201803 150.583 249.554 201.509
201806 155.486 251.989 206.060
201809 163.555 252.439 216.367
201812 134.909 251.233 179.328
201903 163.107 254.202 214.278
201906 184.116 256.143 240.045
201909 171.412 256.759 222.946
201912 192.314 256.974 249.923
202003 212.267 258.115 274.633
202006 247.770 257.797 320.963
202009 295.843 260.280 379.581
202012 331.052 260.474 424.440
202103 356.449 264.877 449.404
202106 389.449 271.696 478.687
202109 512.476 274.310 623.901
202112 457.204 278.802 547.644
202203 340.098 287.504 395.043
202206 300.450 296.311 338.617
202209 283.449 296.808 318.921
202212 324.887 296.797 365.558
202303 329.760 301.836 364.847
202306 290.510 305.109 317.973
202309 288.768 307.789 313.314
202312 306.508 306.746 333.693
202403 317.317 312.332 339.282
202406 240.393 314.175 255.525
202409 267.465 315.301 283.286
202412 234.525 315.605 248.159
202503 241.716 319.799 252.413
202506 263.419 322.561 272.721
202509 249.750 324.800 256.787
202512 276.158 324.054 284.593
202603 255.374 330.213 258.266
202606 268.303 333.952 268.303

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bio-Rad Laboratories (BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of $376.41 is trading 19.1% above its estimated GF Value™ of $316.02. GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.

Key valuation signals for BIO:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $316.02 vs. price of $376.41 (19.1% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Other Exchanges BIO.B:USABUWA:Germany
Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
70GF Score

Get the complete analysis for BIO

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$376.41
Price
$316.02
GF Value